Allakos Inc. - Common Stock (ALLK)

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 million in estimated costs.

ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024.

ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Unusual volume stocks are being observed in Friday's session.

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

Which stocks have an unusual volume on Wednesday?

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's have a look at the gap up and gap down stocks in today's session.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.